competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** Board of Scientific Counselors, NIAA.

**Date:** May 19, 2015.

**Time:** 8:00 a.m. to 8:30 a.m.

**Agenda:** To review and evaluate personal qualifications and performance, and competence of individual investigators.

**Place:** National Institute on Aging, Biomedical Research Center, 3rd Floor Conference Room, 251 Bayview Boulevard, Baltimore, MD 21224.

**Open:** 8:30 a.m. to 11:45 a.m. **Closed:** 11:45 a.m. to 12:45 p.m.

**Agenda:** To review and evaluate personal qualifications and performance, and competence of individual investigators.

**Place:** National Institute on Aging, Biomedical Research Center, 3rd Floor Conference Room, 251 Bayview Boulevard, Baltimore, MD 21224.

**Open:** 12:45 p.m. to 3:00 p.m.

**Agenda:** Committee discussion, individual presentations, laboratory overview.

**Place:** National Institute on Aging, Biomedical Research Center, 3rd Floor Conference Room, 251 Bayview Boulevard, Baltimore, MD 21224.

**Closed:** 3:00 p.m. to 4:00 p.m.

**Agenda:** To review and evaluate personal qualifications and performance, and competence of individual investigators.

**Place:** National Institute on Aging, Biomedical Research Center, 3rd Floor Conference Room, 251 Bayview Boulevard, Baltimore, MD 21224.

**Contact Person:** Luigi Ferrucci, Ph.D., MD, Scientific Director, National Institute on Aging. Giselle Hersh, Division of Workplace Programs, SAMHSA/CSAP, Room 7–1051, One Choke Cherry Road, Rockville, Maryland 20857; 240–276–1000; koretskya@ninds.nih.gov.

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Substance Abuse and Mental Health Services Administration**

**Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies**

**AGENCY:** Substance Abuse and Mental Health Services Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Department of Health and Human Services (HHS) notifies federal agencies of the laboratories and Instrumented Initial Testing Facilities (IITF) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the Federal Register on April 11, 1988 (53 FR 11970), and subsequently revised in the Federal Register on June 9, 1994 (59 FR 29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644); November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); and on April 30, 2010 (75 FR 22809).

A notice listing all currently HHS-certified laboratories and IITFs is published in the Federal Register during the first week of each month. If any laboratory or IITF certification is suspended or revoked, the laboratory or IITF will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines. If any laboratory or IITF has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end and will be omitted from the monthly listing thereafter.

This notice is also available on the Internet at http://beta.samhsa.gov/workplace.

**FOR FURTHER INFORMATION CONTACT:** Giselle Hersh, Division of Workplace Programs, SAMHSA/CSAP, Room 7–1051, One Choke Cherry Road, Rockville, Maryland 20857; 240–276–2600 (voice), 240–276–2610 (fax).

**SUPPLEMENTARY INFORMATION:** The Mandatory Guidelines were initially developed in accordance with Executive Order 12564 and section 503 of Pub. L. 100–71. The “Mandatory Guidelines for Federal Workplace Drug Testing Programs,” as amended in the revised lists above, requires strict standards that laboratories and IITFs must meet in order to conduct drug and specimen validity tests on urine specimens for federal agencies.

To become certified, an applicant laboratory or IITF must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a laboratory or IITF must participate in a quarterly performance testing program plus undergo periodic, on-site inspections.

Laboratories and IITFs in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A HHS-certified laboratory or IITF must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA), which attests that it has met minimum standards.

In accordance with the Mandatory Guidelines dated November 25, 2008 (73 FR 71858), the following HHS-
certified laboratories and IITFs meet the minimum standards to conduct drug and specimen validity tests on urine specimens:

**HHS-Certified Instrumented Initial Testing Facilities:**
- Gamma-Dynacare Medical Laboratories
  - 6628 50th Street NW.
  - Edmonton, AB Canada T6B 2N7
  - 780–784–1190

**HHS-Certified Laboratories:**
- ACM Medical Laboratory, Inc.
  - 625 SW 50th Street
  - Portland, OR 97239
  - 503–429–2264
- Aegis Analytical Laboratories, Inc.
  - 345 Hill Ave.
  - Nashville, TN 37210
  - 615–255–2400
- Alere Toxicology Services
  - 1111 Newton St.
  - Gretna, LA 70053
  - 504–361–8989/800–433–3823
- Alere Toxicology Testing Facilities
  - 450 Southlake Blvd.
  - Richmond, VA 23236
  - 804–378–9130
- Baptist Medical Center-Toxicology Laboratory
  - 11401 I–30
  - Fort Worth, TX 76106
  - 817–601–2345
- Clinical Reference Lab
  - 8433 Quivira Road
  - Lenexa, KS 66215
  - 913–888–8027/800–873–8845
- DrugScan, Inc.
  - 200 Precision Road, Suite 200
  - Horsham, PA 19044
  - 800–233–6432
- ElSohly Laboratories, Inc.
  - 25749 SW Canyon Creek Road, Suite 600
  - Wilsonville, OR 97070
  - 503–486–1023
- Gamma-Dynacare Medical Laboratories
  - A Division of the Gamma-Dynacare Laboratory Partnership
  - 245 Pall Mall Street
  - London, ONT, Canada N6A 1P4
  - 519–679–1630
- Laboratory Corporation of America Holdings
  - 7207 N. Gessner Road
  - Houston, TX 77040
  - 713–856–8288/800–800–2387
- Laboratory Corporation of America Holdings
  - 69 First Ave.
  - Raritan, NJ 08869
- Laboratory Corporation of America Holdings
  - 1904 Alexander Drive
  - Research Triangle Park, NC 27709
- LabOne, Inc. d/b/a Quest Diagnostics
  - 10101 Renner Blvd.
  - Lenexa, KS 66219
  - 913–888–3927/800–873–8845
- MedTox Laboratories, Inc.
  - 402 W. County Road D
  - St. Paul, MN 55112
  - 651–636–7466/800–832–3244
- MetroLab-Legacy Laboratory Services
  - 1225 NE 2nd Ave.
  - Portland, OR 97232
  - 503–413–5295/800–950–5295
- Minnesota Veterans Affairs Medical Center
  - Forensic Toxicology Laboratory
  - 1 Veterans Drive
  - Minneapolis, MN 55417
  - 612–725–2088
- National Toxicology Laboratories, Inc.
  - 1100 California Ave.
  - Bakersfield, CA 93304
  - 661–322–4250/800–350–3515
- One Source Toxicology Laboratory, Inc.
  - 1213 Genoa-Red Bluff
  - Pasadena, TX 77504
  - 888–747–3774
  - (Formerly: University of Texas Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory)
- Pacific Toxicology Laboratories
  - 7438 DeSoto Ave.
  - Chatsworth, CA 91311
  - 800–328–6942
  - (Formerly: Centinela Hospital Airport Toxicology Laboratory)
- Pathology Associates Medical Laboratories
  - 110 West Cliff Dr.
  - Spokane, WA 99204
- Phamatech, Inc.
  - 15175 Innovation Drive
  - San Diego, CA 92128
  - 888–635–5840
- Quest Diagnostics Incorporated
  - 1777 Montreal Circle
  - Tucker, GA 30084
  - 800–729–6432
  - (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories)
- Quest Diagnostics Incorporated
  - 400 Egypt Road
  - Norristown, PA 19403
  - (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories)
- Quest Diagnostics Incorporated
  - 8401 Fallbrook Ave.
  - West Hills, CA 91304
  - 818–737–6370
  - (Formerly: SmithKline Beecham Clinical Laboratories)
- Redwood Toxicology Laboratory
  - 3700650 Westwind Blvd.
  - Santa Rosa, CA 95403
  - 800–255–2159
- Southwest Laboratories
  - 4625 E. Cotton Center Boulevard
  - Suite 177
  - Phoenix, AZ 85040
  - 602–438–8507/800–279–0027
- STARLAB Reference Laboratories
  - 2617 East L Street
  - Tacoma, Washington 98421
  - 800–442–0438
- U.S. Army Forensic Toxicology Drug Testing Laboratory
  - 2490 Wilson St.
  - Fort George G. Meade, MD 20755–5235
  - 301–677–7085
  - *The Standards Council of Canada (SCC) voted to end its Laboratory Accreditation Program for Substance Abuse (LAPSA) effective May 12, 1998. Laboratories certified through that program were accredited to conduct forensic urine drug testing as required by U.S. Department of Transportation (DOT) regulations. As of that date, the
certification of those accredited Canadian laboratories will continue under DOT authority. The responsibility for conducting quarterly performance testing plus periodic on-site inspections of those LAPSA-accredited laboratories was transferred to the U.S. HHS, with the HHS’ NLCP contractor continuing to have an active role in the performance testing and laboratory inspection processes. Other Canadian laboratories wishing to be considered for the NLCP may apply directly to the NLCP contractor just as U.S. laboratories do. Upon finding a Canadian laboratory to be qualified, HHS will recommend that DOT certify the laboratory (Federal Register, July 16, 1996) as meeting the minimum standards of the Mandatory Guidelines published in the Federal Register on April 30, 2010 (75 FR 22809). After receiving DOT certification, the laboratory will be included in the monthly list of HHS-certified laboratories and participate in the NLCP certification maintenance program.

Janine Denis Cook,
Chemist Division of Workplace Programs,
Center for Substance Abuse Prevention,
SAMHSA.

[FR Doc. 2015–07423 Filed 3–31–15; 8:45 am]
BILLING CODE 4162–20–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Toxic Substances and Disease Registry

[Docket No. ATSDR–2015–0001]

Proposed Substances To Be Evaluated for Set 29 Toxicological Profiles

AGENCY: Agency for Toxic Substances and Disease Registry (ATSDR), Department of Health and Human Services (HHS).

ACTION: Request for comments on the proposed substances to be evaluated for Set 29 toxicological profiles.

SUMMARY: ATSDR is initiating the development of its 29th set of toxicological profiles (CERCLA Set 29). This notice announces the list of proposed substances that will be evaluated for CERCLA Set 29 toxicological profile development. ATSDR’s Division of Toxicology and Human Health Sciences is soliciting public nominations from the list of proposed substances to be evaluated for toxicological profile development. ATSDR also will consider the nomination of any additional, non-CERCLA substances that may have public health implications, on the basis of ATSDR’s authority to prepare toxicological profiles for substances not found at sites on the National Priorities List. The agency will do so in order to “. . . establish and maintain inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and to support the site-specific response actions conducted by ATSDR, as otherwise necessary.

DATES: Nominations from the Substance Priority List and/or additional substances must be submitted within 30 days of the publication of this notice.

ADDRESSES: You may submit nominations, identified by Docket No. ATSDR–2015–0001, by any of the following methods:


* Mail: Division of Toxicology and Human Health Sciences, 1600 Clifton Rd. NE., MS F–57, Atlanta, Ga., 30333.

Instructions: All submissions must include the agency name and docket number for this notice. All relevant comments will be posted without change. This means that no confidential business information or other confidential information should be submitted in response to this notice. Refer to the section Submission of Nominations (below) for the specific information required.

FOR FURTHER INFORMATION CONTACT: For further information, please contact Commander Jessilyn B. Taylor, Division of Toxicology and Human Health Sciences, 1600 Clifton Rd. NE., MS F–57, Atlanta, Ga., 30333. Email: tpcandidatecomments@cdc.gov; phone: 1–800–232–4636.

SUPPLEMENTARY INFORMATION: The Superfund Amendments and Reauthorization Act of 1986 (SARA) [42 U.S.C. 9601 et seq.] amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund) [42 U.S.C. 9601 et seq.] by establishing certain requirements for ATSDR and the U.S. Environmental Protection Agency (EPA) with regard to hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL). Among these statutory requirements is a mandate for the Administrator of ATSDR to prepare toxicological profiles for each substance included on the Priority List of Hazardous Substances. This list identifies 275 hazardous substances that ATSDR and EPA have determined pose the most significant current potential threat to human health. The availability of the revised list of the 275 priority substances was announced in the Federal Register on May 28, 2014 (79 FR 30613). For prior versions of the list of substances, see Federal Register notices dated April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); February 28, 1994 (59 FR 9486); April 29, 1996 (61 FR 18744); November 17, 1997 (62 FR 61332); October 21, 1999 (64 FR 56792); October 25, 2001 (66 FR 54014); November 7, 2003 (68 FR 63098); December 7, 2005 (70 FR 72840); and March 6, 2008 (73 FR 12178); November 3, 2011 (76 FR 68193).

Substances To Be Evaluated for Set 29 Toxicological Profiles

Each year, ATSDR develops a list of substances to be considered for toxicological profile development. The Set 29 nomination process includes consideration of all substances on ATSDR’s Priority List of Hazardous Substances, also known as the Substance Priority List (SPL), as well as other substances nominated by the public. The 275 substances on the SPL will be considered for Set 29 Toxicological Profile development. This list may be found at the following Web site: www.atsdr.cdc.gov/SPL.

Submission of Nominations for the Evaluation of Set 29 Proposed Substances

Today’s notice invites voluntary public nominations for substances included on the SPL and for substances not listed on the SPL. All nominations should include the full name of the nominator, affiliation, and email address. When nominating a non-SPL substance, please include the rationale for the nomination. Please note that email addresses will not be posted on regulations.gov.

ATSDR will evaluate all data and information associated with nominated substances and will determine the final list of substances to be chosen for toxicological profile development. Substances will be chosen according to ATSDR’s specific guidelines for selection. These guidelines can be found in the Selection Criteria announced in the Federal Register on May 7, 1993 (58 FR 27286–27287). A hard copy of the Selection Criteria is available upon request or may be accessed at: http://www.atsdr.cdc.gov/toxprofiles/guidance/criteria_for_selecting_tp_support.pdf.